Abstract 241P
Background
Human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV-associated OPSCC) is well known to have a relatively indolent behavior, and it should be staged separately. P16 is a useful surrogate marker for HPV status in OP region. However, the low prevalence of HPV infection in Taiwan (lower than 30%) may cause increased possibility of false positive for p16 staining. This study is aimed to determine the concordance of p16 IHC stain and HPV RNA ISH in Taiwan population.
Methods
There were 141 oropharyngeal cancer patients are retrieved from the archives of VGHTC from 2016 to 2020. HE stain was done and reviewed by 2 pathologist and p16 IHC stain was performed for all cases. Forty-nine (34.8%) of all cases were p16(+) oropharyngeal cancer. HPV-ISH was done for p16(+) oropharyngeal cancer patients.
Results
HPV-ISH found 44 (89.7%) of 49 cases were HPV-ISH (+). On univariate analysis, p16 (+) oropharyngeal cancer patients had better 3-year overall survival (90.4 % vs. 73.4 %, p=0.02) and 3-year disease-free survival (95.4% vs. 65.3%, p=0.0005) than p16(-) oropharyngeal cancer patients. HPV-ISH (+) oropharyngeal cancer patients also had better 3-year overall survival (92.0 % vs. 73.5 %, p=0.02) and 3-year disease-free survival (94.9% vs. 67.4%, p=0.002) than HPV-ISH(-) oropharyngeal cancer patients. We also found p16(+)HPVISH(+) oropharngeal cancer patients had better 3-year disease-free survival than p16(-)HPVISH(-) oropharngeal cancer patients (94.9% vs. 65.3%, p=0.002).
Conclusions
By far, p16 is still a useful surrogate marker for OPSCC in Taiwan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
150P - Use of neoadjuvant chemotherapy for non-metastatic muscle-invasive bladder cancer in Asia-Pacific
Presenter: Ravindran Kanesvaran
Session: Poster viewing 03
Resources:
Abstract
Slides
151P - Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer: Real-world analysis of chemotherapy use and impact on patient outcomes
Presenter: Alison Hiong
Session: Poster viewing 03
152P - An epidemiologic study on PD-L1 expression with clinical observation of initial treatment pattern in the Chinese muscle invasive urothelial bladder carcinoma patients
Presenter: Liqun Zhou
Session: Poster viewing 03
153P - Efficacy and toxicity of HER2-targeted antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review
Presenter: Tiago Padua
Session: Poster viewing 03
154P - Can urine cytology predict variants of bladder cancer?
Presenter: Hikaru Mikami
Session: Poster viewing 03
155P - Search for circulating tumor cells in patients with urothelial cancer
Presenter: Irina Kruglova
Session: Poster viewing 03
156P - The association between response to enfortumab vedotin therapy and primary tumor location in Japanese urothelial carcinoma patients
Presenter: Nozomi Hayakawa
Session: Poster viewing 03
163P - Outcomes and toxicity of fosfesterol in metastatic castration-resistant prostate cancer: Experience from a low middle income country
Presenter: Manuprasad Avaronnan
Session: Poster viewing 03
164P - F-18 PSMA-PET/CT-guided percutaneous prostate biopsy
Presenter: Rajender Kumar
Session: Poster viewing 03
165P - Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer
Presenter: Richard Kelly
Session: Poster viewing 03